biosimilars

Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Endpoints
drug pricing
biosimilars
Flag link:
FDA approves first biosimilar for NHL
FDA approves first biosimilar for NHL
BioCentury
Celltrion
Teva Pharmaceutical
non-Hodgkin's lymphoma
Truxima
biosimilars
rituximab
Flag link:
Boehringer dropping ex-U.S. biosimilars programs
Boehringer dropping ex-U.S. biosimilars programs
BioCentury
Boehringer Ingelheim
biosimilars
Flag link:
Momenta Moves On
Momenta Moves On
Motley Fool
Momenta
earnings
biosimilars
M281
M254
Flag link:
Novartis Calls for FDA Enforcement Against Biosimilar Misinformation
Novartis Calls for FDA Enforcement Against Biosimilar Misinformation
RAPS.org
Novartis
FDA
biosimilars
citizen petitions
Flag link:
Pfizer launches biosimilar version of Amgen's Epogen
Pfizer launches biosimilar version of Amgen's Epogen
Biopharma Dive
Pfizer
biosimilars
Amgen
Epogen
JNJ
Procrit
anemia
Flag link:
The dynamics of the biosimilars market
The dynamics of the biosimilars market
GoinPharma
biosimilars
Flag link:
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Reuters
Coherus Biosciences
Amgen
biosimilars
Neulasta
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:
AbbVie staves off 6th Humira biosimilar in US
AbbVie staves off 6th Humira biosimilar in US
Biopharma Dive
AbbVie
Humira
biosimilars
Momenta Pharmaceuticals
Flag link:
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
BioSpace
Biogen
Samsung Bioepis
biosimilars
Flag link:
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Flag link:
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Endpoints
Coherus
Neulasta
Mylan
biosimilars
Amgen
Flag link:
Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Novartis
Sandoz
rituximab
biosimilars
Roche
Flag link:
Amgen reckons with biosimilar and pricing pressures
Amgen reckons with biosimilar and pricing pressures
Biopharma Dive
Amgen
earnings
biosimilars
Aimovig
Flag link:
Novartis wins US nod for Humira biosimilar, but focus now on Europe
Novartis wins US nod for Humira biosimilar, but focus now on Europe
Biopharma Dive
Novartis
Hyrimoz
biosimilars
Humira
AbbVie
FDA
Flag link:
Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say
Genentech staff ‘funneled secrets to Taiwan biosimilar firm,’ prosecutors say
Fierce Biotech
Genentech
trade secrets
Taiwan
biosimilars
Flag link:
This Big Pharma Bet Isn't Paying Off Yet
This Big Pharma Bet Isn't Paying Off Yet
Motley Fool
Big Pharma
biosimilars
Novartis
Amgen
Merck
Pfizer
Biogen
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
Motley Fool
Momenta Pharmaceuticals
Teva Pharmaceuticals
Copaxone
Novartis
biosimilars
Glatopa
Flag link:

Pages